Danaher Corporation $DHR Shares Sold by Carmignac Gestion

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Carmignac Gestion lowered its position in Danaher Corporation (NYSE:DHR - Free Report) by 39.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 93,370 shares of the conglomerate's stock after selling 61,616 shares during the period. Carmignac Gestion's holdings in Danaher were worth $19,150,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of DHR. Nuveen LLC purchased a new stake in Danaher in the first quarter valued at approximately $833,941,000. GAMMA Investing LLC boosted its position in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after purchasing an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP boosted its position in Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after purchasing an additional 1,601,800 shares in the last quarter. Invesco Ltd. boosted its position in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Danaher by 460.6% in the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after purchasing an additional 1,107,998 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

DHR has been the topic of several recent research reports. Guggenheim restated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. TD Cowen upped their price objective on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Argus lowered their price objective on Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. Finally, Evercore ISI lowered their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Trading Down 3.4%

Shares of DHR traded down $7.2480 during midday trading on Thursday, reaching $204.1520. The company had a trading volume of 3,172,582 shares, compared to its average volume of 4,191,163. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The stock has a market cap of $146.18 billion, a PE ratio of 43.44, a price-to-earnings-growth ratio of 2.95 and a beta of 0.73. The firm has a 50 day simple moving average of $200.45 and a 200-day simple moving average of $199.55. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.